Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases

Inflamm Bowel Dis. 2021 Oct 18;27(10):1698-1702. doi: 10.1093/ibd/izab112.

¹ Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St. Louis, Missouri, USA.
² Department of Internal Medicine, St. Luke's Hospital, Chesterfield, Missouri, USA.
³ Department of Medicine, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
⁴ Division of Gastroenterology, Brooke Army Medical Center, Fort Sam Houston, Texas, USA.
⁵ Department of Radiology, Mallinckrodt Institute of Radiology, Washington University in Saint Louis, St. Louis, Missouri, USA.
⁶ Department of Medicine, University of Central Florida, Orlando, Florida, USA.

No abstract available

Keywords: biologics; combination therapy; inflammatory bowel disease; tofacitinib.

Publication types